Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells
Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is a leading asexual blood-stage vaccine candidate for malaria. In preparation for clinical trials, a full-length PfRH5 protein vaccine called “RH5.1” was produced as a soluble product under cGMP using the ExpreS2 platform (based o...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Nature Publishing Group
2018
|
| _version_ | 1797089265482465280 |
|---|---|
| author | Jin, J Tarrant, R Bolam, E Angell-Manning, P Soegaard, M Pattinson, D Dulal, P Silk, S Marshall, J Dabbs, R Nugent, F Barrett, J Hjerrild, K Poulsen, L Jørgensen, T Brenner, T Baleanu, I Parracho, H Tahiri-Alaoui, A Whale, G Moyle, S Payne, R Minassian, A Higgins, M Detmers, F Lawrie, A Douglas, A Smith, R De Jongh, W Berrie, E Ashfield, R Draper, S |
| author_facet | Jin, J Tarrant, R Bolam, E Angell-Manning, P Soegaard, M Pattinson, D Dulal, P Silk, S Marshall, J Dabbs, R Nugent, F Barrett, J Hjerrild, K Poulsen, L Jørgensen, T Brenner, T Baleanu, I Parracho, H Tahiri-Alaoui, A Whale, G Moyle, S Payne, R Minassian, A Higgins, M Detmers, F Lawrie, A Douglas, A Smith, R De Jongh, W Berrie, E Ashfield, R Draper, S |
| author_sort | Jin, J |
| collection | OXFORD |
| description | Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is a leading asexual blood-stage vaccine candidate for malaria. In preparation for clinical trials, a full-length PfRH5 protein vaccine called “RH5.1” was produced as a soluble product under cGMP using the ExpreS2 platform (based on a Drosophila melanogaster S2 stable cell line system). Following development of a high-producing monoclonal S2 cell line, a master cell bank was produced prior to the cGMP campaign. Culture supernatants were processed using C-tag affinity chromatography followed by size exclusion chromatography and virus-reduction filtration. The overall process yielded >400 mg highly pure RH5.1 protein. QC testing showed the MCB and the RH5.1 product met all specified acceptance criteria including those for sterility, purity, and identity. The RH5.1 vaccine product was stored at −80 °C and is stable for over 18 months. Characterization of the protein following formulation in the adjuvant system AS01B showed that RH5.1 is stable in the timeframe needed for clinical vaccine administration, and that there was no discernible impact on the liposomal formulation of AS01B following addition of RH5.1. Subsequent immunization of mice confirmed the RH5.1/AS01B vaccine was immunogenic and could induce functional growth inhibitory antibodies against blood-stage P. falciparum in vitro. The RH5.1/AS01B was judged suitable for use in humans and has since progressed to phase I/IIa clinical trial. Our data support the future use of the Drosophila S2 cell and C-tag platform technologies to enable cGMP-compliant biomanufacture of other novel and “difficult-to-express” recombinant protein-based vaccines. |
| first_indexed | 2024-03-07T03:01:53Z |
| format | Journal article |
| id | oxford-uuid:b13b89ea-c608-4b5f-b625-687187decd62 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:01:53Z |
| publishDate | 2018 |
| publisher | Nature Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:b13b89ea-c608-4b5f-b625-687187decd622022-03-27T04:02:35ZProduction, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cellsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b13b89ea-c608-4b5f-b625-687187decd62EnglishSymplectic Elements at OxfordNature Publishing Group2018Jin, JTarrant, RBolam, EAngell-Manning, PSoegaard, MPattinson, DDulal, PSilk, SMarshall, JDabbs, RNugent, FBarrett, JHjerrild, KPoulsen, LJørgensen, TBrenner, TBaleanu, IParracho, HTahiri-Alaoui, AWhale, GMoyle, SPayne, RMinassian, AHiggins, MDetmers, FLawrie, ADouglas, ASmith, RDe Jongh, WBerrie, EAshfield, RDraper, SPlasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is a leading asexual blood-stage vaccine candidate for malaria. In preparation for clinical trials, a full-length PfRH5 protein vaccine called “RH5.1” was produced as a soluble product under cGMP using the ExpreS2 platform (based on a Drosophila melanogaster S2 stable cell line system). Following development of a high-producing monoclonal S2 cell line, a master cell bank was produced prior to the cGMP campaign. Culture supernatants were processed using C-tag affinity chromatography followed by size exclusion chromatography and virus-reduction filtration. The overall process yielded >400 mg highly pure RH5.1 protein. QC testing showed the MCB and the RH5.1 product met all specified acceptance criteria including those for sterility, purity, and identity. The RH5.1 vaccine product was stored at −80 °C and is stable for over 18 months. Characterization of the protein following formulation in the adjuvant system AS01B showed that RH5.1 is stable in the timeframe needed for clinical vaccine administration, and that there was no discernible impact on the liposomal formulation of AS01B following addition of RH5.1. Subsequent immunization of mice confirmed the RH5.1/AS01B vaccine was immunogenic and could induce functional growth inhibitory antibodies against blood-stage P. falciparum in vitro. The RH5.1/AS01B was judged suitable for use in humans and has since progressed to phase I/IIa clinical trial. Our data support the future use of the Drosophila S2 cell and C-tag platform technologies to enable cGMP-compliant biomanufacture of other novel and “difficult-to-express” recombinant protein-based vaccines. |
| spellingShingle | Jin, J Tarrant, R Bolam, E Angell-Manning, P Soegaard, M Pattinson, D Dulal, P Silk, S Marshall, J Dabbs, R Nugent, F Barrett, J Hjerrild, K Poulsen, L Jørgensen, T Brenner, T Baleanu, I Parracho, H Tahiri-Alaoui, A Whale, G Moyle, S Payne, R Minassian, A Higgins, M Detmers, F Lawrie, A Douglas, A Smith, R De Jongh, W Berrie, E Ashfield, R Draper, S Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells |
| title | Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells |
| title_full | Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells |
| title_fullStr | Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells |
| title_full_unstemmed | Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells |
| title_short | Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells |
| title_sort | production quality control stability and potency of cgmp produced plasmodium falciparum rh5 1 protein vaccine expressed in drosophila s2 cells |
| work_keys_str_mv | AT jinj productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT tarrantr productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT bolame productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT angellmanningp productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT soegaardm productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT pattinsond productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT dulalp productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT silks productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT marshallj productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT dabbsr productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT nugentf productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT barrettj productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT hjerrildk productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT poulsenl productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT jørgensent productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT brennert productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT baleanui productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT parrachoh productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT tahirialaouia productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT whaleg productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT moyles productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT payner productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT minassiana productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT higginsm productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT detmersf productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT lawriea productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT douglasa productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT smithr productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT dejonghw productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT berriee productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT ashfieldr productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells AT drapers productionqualitycontrolstabilityandpotencyofcgmpproducedplasmodiumfalciparumrh51proteinvaccineexpressedindrosophilas2cells |